BUFFALO GROVE, Ill.--(BUSINESS WIRE)--Dec. 19, 2005--Akorn, Inc. (AMEX:AKN) today announced that it has signed a Letter of Intent with Natco Pharma Limited (NSE:NATCOPHARM) (MUMBAI:524816), located in Hyderabad, India, to develop and supply two ANDA oral tablet drug products for cancer patients suffering from nausea and vomiting. The Letter of Intent anticipates executing a Definitive Agreement within ninety days upon Terms and Conditions agreeable to both Akorn and Natco.
